Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryosuke Muroyama

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|January 17, 2013
A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC regionYuji Urabe, Hidenori Ochi, Naoya Kato, et al.
International Journal of Molecular Sciences|October 14, 2022
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B VirusYaojia Ma, Shingo Nakamoto, Junjie Ao, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 2022
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosisTakafumi Sakuma, Masato Nakamura, Tetsuhiro Chiba, et al.
Biochemical and Biophysical Research Communications|March 6, 2021
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsJunjie Ao, Tetsuhiro Chiba, Shuhei Shibata, et al.
International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.
Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.
International Journal of Clinical Oncology|June 15, 2022
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysisYusuke Ozeki, Naoya Kanogawa, Sadahisa Ogasawara, et al.
BMJ Open|April 9, 2022
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
Scientific Reports|March 6, 2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|January 17, 2013
A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC regionYuji Urabe, Hidenori Ochi, Naoya Kato, et al.
International Journal of Molecular Sciences|October 14, 2022
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B VirusYaojia Ma, Shingo Nakamoto, Junjie Ao, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 2022
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosisTakafumi Sakuma, Masato Nakamura, Tetsuhiro Chiba, et al.
Biochemical and Biophysical Research Communications|March 6, 2021
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsJunjie Ao, Tetsuhiro Chiba, Shuhei Shibata, et al.
International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.
Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.
International Journal of Clinical Oncology|June 15, 2022
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysisYusuke Ozeki, Naoya Kanogawa, Sadahisa Ogasawara, et al.
BMJ Open|April 9, 2022
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
Scientific Reports|March 6, 2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, et al.
Pageof 6